# Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

> **NCT04728035** · PHASE1 · COMPLETED · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Irinotecan Liposome Injection

## Key facts

- **NCT ID:** NCT04728035
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-31
- **Primary completion:** 2023-06-05
- **Final completion:** 2024-06-05
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728035, "Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04728035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*